Influence of neutralizing antibodies to adalimumab and infliximab on the treatment of psoriasis

British Journal of Dermatology

Volumn 170, Issue 4, 2014, Pages 922-929

  Bito, T ^a   Nishikawa, R ^a   Hatakeyama, M ^a   Kikusawa, A ^a   Kanki, H ^a   Nagai, H ^a   Sarayama, Y ^b   Ikeda, T ^c   Yoshizaki, H ^d   Seto, H ^e   Adachi, A ^f   Horikawa, T ^g   Oka, M ^a   Nishigori, C ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KOBE ROSAI HOSPITAL   (Japan)

^c KOBE CITY MEDICAL CENTER WEST HOSPITAL   (Japan)

^d HYOGO PREFECTURAL AWAJI HOSPITAL   (Japan)

^e Takatsuki   (Japan)

^f Department of Neurosurgery Hyogo Prefectural Kakogawa Medical Center   (Japan)

^g NISHI KOBE MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB; NEUTRALIZING ANTIBODY; BIOLOGICAL FACTOR; DERMATOLOGICAL AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; DRUG BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RADIOIMMUNOASSAY; SYSTEMIC THERAPY; THERAPY; THERAPY EFFECT; ANTIBODY PRODUCTION; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; PHYSIOLOGY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEUTRALIZING; ANTIBODY FORMATION; BIOLOGICAL FACTORS; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; TREATMENT OUTCOME;

EID: 84907872825     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12791     Document Type: Article

References (15)

1. Ordás I, Feagan BG, Sandborn WJ,. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012; 10: 1079-87.
2. Gordon KB, Langley RG, Leonardi C, et al,. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598-606.
3. Menter A, Tyring SK, Gordon K, et al,. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106-15.
4. Leman J, Burden AD,. Sequential use of biologics in the treatment of moderate-to-severe plaque psoriasis. Br J Dermatol 2012; 167 (Suppl. 3): S12-20.
5. Smith CH, Anstey AV, Barker JN, et al,. British Association of Dermatologists' guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009; 161: 987-1019.
6. Lecluse LL, Driessen RJ, Spuls PI, et al,. Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol 2010; 146: 127-32.
7. Takahashi H, Tsuji H, Ishida-Yamamoto A, Iizuka H,. Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis. J Dermatol 2013; 40: 39-42.
8. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al,. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-6.
9. Torii H, Nakagawa H,. Japanese Infliximab Study investigators. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010; 59: 40-9.
10. van Schouwenburg PA, Krieckaert CL, Rispens T, et al,. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis 2013; 72: 1680-6.
11. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al,. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305: 1460-8.
12. Weisman MH, Moreland LW, Furst DE, et al,. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003; 25: 1700-21.
13. Granneman RG, Zhang Y, Noertersheuser PA, et al,. Pharmacokinetic/ pharmacodynamic (PK/PD) relationships of adalimumab (Humira, Abbott) in rheumatoid arthritis (RA) patients during phase II/III clinical trials. Arthritis Rheum 2003; 48 (Suppl.): S140-1.
14. Mahil SK, Arkir Z, Richards G, et al,. Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study. Br J Dermatol 2013; 169: 306-13.
15. Takahashi H, Tsuji H, Hashimoto Y, et al,. Serum cytokines and growth factor levels in Japanese patients with psoriasis. Clin Exp Dermatol 2010; 35: 645-9.